Schrödinger and Eli Lilly Expand Access to AI Drug Discovery with TuneLab Integration

Schrödinger has partnered with Eli Lilly to make Lilly’s AI-driven drug discovery platform, TuneLab, available within Schrödinger’s cloud-based molecular design environment, LiveDesign. The collaboration aims to broaden access to advanced artificial intelligence tools that have traditionally been limited to large pharmaceutical organizations.

TuneLab is an AI and machine-learning platform developed internally by Eli Lilly and trained on decades of proprietary drug discovery data. The platform is designed to help scientists predict molecular properties, optimize compound design, and improve decision-making during early-stage drug discovery. By integrating TuneLab into LiveDesign, Schrödinger enables researchers to access these AI models directly within a single collaborative workspace.

LiveDesign is widely used by pharmaceutical and biotechnology companies to manage molecular design workflows, experimental data, and computational modeling. The addition of TuneLab allows medicinal and computational chemists to combine physics-based simulations, AI predictions, and experimental insights without switching between disconnected tools. This integration is intended to streamline workflows and reduce friction during early discovery stages.

A key objective of the partnership is to lower barriers for biotech companies seeking to adopt AI-driven discovery methods. Developing in-house AI platforms requires significant resources, including data infrastructure, specialized talent, and long development timelines. By embedding TuneLab into an existing commercial platform, Schrödinger and Lilly are making advanced predictive capabilities more accessible to smaller and mid-sized biotech firms.

Another important aspect of TuneLab is its federated learning approach. This design allows users to benefit from AI models trained on large datasets without exposing their own proprietary data. For biotech companies, data privacy and intellectual property protection remain major concerns when adopting third-party AI tools. The federated model helps address these issues while still enabling continuous improvement of predictive performance.

The collaboration also reflects a broader industry shift toward platform-based drug discovery ecosystems. Rather than relying on isolated, proprietary systems, pharmaceutical companies are increasingly integrating AI tools into shared environments that support collaboration across teams and organizations. This approach aligns with the growing complexity of drug discovery, where chemistry, biology, data science, and regulatory considerations must be evaluated in parallel.

For Eli Lilly, the partnership represents a strategic move to extend the reach of its internal AI capabilities beyond its own R&D operations. By offering TuneLab through Schrödinger’s LiveDesign platform, Lilly positions its technology as part of the wider drug discovery infrastructure used across the biotech sector. This model allows Lilly to influence how AI is applied in early discovery while maintaining control over its core intellectual property.

Schrödinger, meanwhile, strengthens LiveDesign’s position as a central hub for AI-enabled drug discovery. The integration enhances the platform’s value proposition by combining Schrödinger’s physics-based modeling expertise with Lilly’s data-driven AI models. This hybrid approach reflects the industry’s recognition that neither AI nor physics-based methods alone are sufficient to address the complexity of modern drug development.

The partnership comes at a time when biotech companies are under increasing pressure to improve R&D productivity. Rising development costs, tighter funding environments, and heightened regulatory scrutiny have intensified the need for tools that can reduce early-stage risk and accelerate timelines. AI-enabled platforms like TuneLab and LiveDesign are being positioned as solutions to help teams make better decisions earlier in the discovery process.

By making TuneLab available within LiveDesign, Schrödinger and Eli Lilly are not claiming to replace traditional drug discovery methods. Instead, the collaboration signals a practical step toward integrating AI into everyday scientific workflows, with the goal of improving efficiency, reducing uncertainty, and ultimately increasing the probability that promising science reaches patients.